Mengying Li, MSPH, PhD

Regeneron Pharmaceuticals, Inc.

Poster(s):

• (C-211) Immune-mediated adverse events in patients with high-risk melanoma receiving immune checkpoint inhibitors in adjuvant and first-line treatment settings: a real-world analysis
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (C-207) Implementing robust machine learning pipelines with real-world data: identifying predictors of immune mediated adverse events among patients with advanced melanoma treated with immune checkpoint inhibitors
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (C-153) Mind the Gap: a literature review to assess definitions of treatment discontinuation in oncology studies
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (SLB-025) Second Primary Malignancy in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anti-Cancer Therapy: A Real-World Evidence from a Large US National Claims Database
  Monday, August 25, 2025

  11:45 AM - 12:45 PM ET

• (C-214) Second Primary Malignancy in Patients with Multiple Myeloma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anticancer Therapy: A Comparative Study Using a Real-World Database
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET